Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Jianxiang Wang
CONTACT
Lead
Institute of Hematology & Blood Diseases Hospital, China
This study will utilize CD180 CART cells to treat CD180-positive relapsed or refractory hematological malignancies, especially AML and B-ALL/LBL patients. Two cohorts were established: (1) relapsed and refractory AML cohort; and (2) relapsed and refractory B-ALL/LBL cohort. A 3+3 dose escalation and rapid titration design was used to explore the maximum tolerated dose for each cohort. 3+3 dose escalation CART dose groups were (1) 0.5×10\^6 CART cells/kg; (2)1×10\^6 CART cells/kg;(3) 3×10\^6 CART cells/kg. A minimum of 6 and a maximum of 12 patients are expected to be enrolled in each cohort. Fludarabine and cyclophosphamide-based preconditioning should be performed within 1 week prior to CD180 CART infusion. CD180 CART can be infused on D-1 provided that the requirement of 24 hours after completion of preconditioning is met. The objective of the study was to evaluate the safety and efficacy of CD180 CART cells in the treatment of patients with relapsed/refractory CD180-positive hematological malignancies.
Age
18–70
Sex
ALL
Healthy volunteers
Not accepted
